CSPC Pharmaceutical (HKG:1093) obtained drug registration approval for the budesonide enteric-coated capsules from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.
The drug is indicated to treat adult patients with primary immunoglobulin A nephropathy at risk of disease progression to reduce the loss of renal function.